Last reviewed · How we verify
NCT06099626
Study of Clinical Features of Patients With Autoimmune Liver Disease Complicated With Covid-19 and the Immune Mechanism Affecting Prognosis
trial testing Different types of disease in Autoimmune Liver Disease, COVID-19 in 200 participants. Status unknown.
30 June 2024
Quick facts
| Lead sponsor | The Second Affiliated Hospital of Chongqing Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 January 2023 |
| Primary completion | 30 June 2024 |
| Estimated completion | 30 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Different types of disease
Conditions studied
- Autoimmune Liver Disease, COVID-19 — all drugs for Autoimmune Liver Disease, COVID-19 →
Sponsor
The Second Affiliated Hospital of Chongqing Medical University
Who can join
Eligibility, any sex, with Autoimmune Liver Disease, COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
With the decreasing virulence of omicrons strain, the current domestic epidemic prevention policy has been changed based on the health of the people and the development needs of the country. At present, the infection rate of the novel coronavirus in China is rising rapidly. Previous studies have found that patients with chronic liver disease are more likely to be co-infected with coronavirus disease 2019 and have a worse prognosis. Based on its unique immune mechanism and therapeutic drugs, patients with autoimmune liver disease also have very different manifestations after infection with the novel coronavirus. By observing the clinical characteristics and prognosis of patients with autoimmune liver disease complicated with coronavirus disease 2019, this study analyzed the roles of vaccines, immunosuppressive agents and ursodeoxycholic acid , and explored the immune mechanism behind them, so as to seek new anti-coronavirus disease 2019 drugs and provide new strategies for clinical prevention and treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06099626
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The Second Affiliated Hospital of Chongqing Medical University trials
Trials by the same sponsor.
- NCT07534046 — Impact of Metabolic Disorders on cACLD Outcomes · not yet recruiting
- NCT07465003 — Cohort Study of Chronic Liver Disease Complicated by Sepsis · not yet recruiting
- NCT07339644 — Functional Lung Avoidance Radiotherapy Guided by 4DCT Pulmonary Ventilation Function Imaging: A Prospective Single-arm C · NA · recruiting
- NCT07048782 — Development and Validation of a Risk Prediction Model for Postoperative Visceral Pain in Abdominal Surgery Patients · not yet recruiting
- NCT07033949 — Effect of Green Light Exposure at Different Times on the Pain of Subjects · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06099626 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Second Affiliated Hospital of Chongqing Medical University
- Last refreshed: 25 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06099626.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing